Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans

C. N. Andrews, Adil Eddie Bharucha, Michael Camilleri, Phillip Anson Low, B. M. Seide, D. D. Burton, K. K. Nickander, K. L. Baxter, A. R. Zinsmeister

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In humans, glucagon-like peptide-1 (GLP-1) delays gastric emptying by inhibiting vagal activity and also increases gastric volumes, by unclear mechanisms. Because GLP-1 inhibits intestinal motility by stimulating the sympathetic nervous system in rats, we assessed the effects of a GLP-1 agonist and yohimbine, an α2-adrenergic antagonist, on gastric volumes in humans. In this double-blind study, 32 healthy volunteers were randomized to placebo, a GLP-1 agonist, yohimbine or GLP-1 and yohimbine. Gastric volumes (fasting predrug and postdrug, and postprandial postdrug) were measured by 99mTc single photon emission computed tomography imaging. Plasma catecholamines and haemodynamic parameters were assessed. Compared with placebo, GLP-1 increased (P = 0.03) but yohimbine did not affect fasting gastric volume. However, GLP-1 plus yohimbine increased (P < 0.001) postprandial gastric accommodation vs placebo and vs GLP-1 alone [postprandial volume change = 542 ± 29 mL (mean ± SEM, placebo), 605 ± 31 mL (GLP-1), 652 ± 54 mL (yohimbine) and 810 ± 37 mL (GLP-1 and yohimbine)]. Plasma noradrenaline and dihydroxyphenylglycol concentrations were higher for yohimbine vs placebo and for GLP-1 and yohimbine vs GLP-1. Yohimbine stimulates central sympathetic activity and in combination with GLP-1, augments postprandial accommodation in humans.

Original languageEnglish (US)
Pages (from-to)716-723
Number of pages8
JournalNeurogastroenterology and Motility
Volume19
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

Glucagon-Like Peptide 1
Yohimbine
Stomach
Placebos
Fasting
Adrenergic Antagonists
Gastrointestinal Motility
Gastric Emptying
Sympathetic Nervous System
Single-Photon Emission-Computed Tomography
Double-Blind Method
Catecholamines
Norepinephrine
Healthy Volunteers

Keywords

  • Accommodation
  • GLP-1
  • Stomach
  • Stress
  • Sympathetic
  • Yohimbine

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology
  • Neuroscience(all)

Cite this

Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans. / Andrews, C. N.; Bharucha, Adil Eddie; Camilleri, Michael; Low, Phillip Anson; Seide, B. M.; Burton, D. D.; Nickander, K. K.; Baxter, K. L.; Zinsmeister, A. R.

In: Neurogastroenterology and Motility, Vol. 19, No. 9, 09.2007, p. 716-723.

Research output: Contribution to journalArticle

Andrews, C. N. ; Bharucha, Adil Eddie ; Camilleri, Michael ; Low, Phillip Anson ; Seide, B. M. ; Burton, D. D. ; Nickander, K. K. ; Baxter, K. L. ; Zinsmeister, A. R. / Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans. In: Neurogastroenterology and Motility. 2007 ; Vol. 19, No. 9. pp. 716-723.
@article{28da80dc2b7645099897eea1e538c48c,
title = "Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans",
abstract = "In humans, glucagon-like peptide-1 (GLP-1) delays gastric emptying by inhibiting vagal activity and also increases gastric volumes, by unclear mechanisms. Because GLP-1 inhibits intestinal motility by stimulating the sympathetic nervous system in rats, we assessed the effects of a GLP-1 agonist and yohimbine, an α2-adrenergic antagonist, on gastric volumes in humans. In this double-blind study, 32 healthy volunteers were randomized to placebo, a GLP-1 agonist, yohimbine or GLP-1 and yohimbine. Gastric volumes (fasting predrug and postdrug, and postprandial postdrug) were measured by 99mTc single photon emission computed tomography imaging. Plasma catecholamines and haemodynamic parameters were assessed. Compared with placebo, GLP-1 increased (P = 0.03) but yohimbine did not affect fasting gastric volume. However, GLP-1 plus yohimbine increased (P < 0.001) postprandial gastric accommodation vs placebo and vs GLP-1 alone [postprandial volume change = 542 ± 29 mL (mean ± SEM, placebo), 605 ± 31 mL (GLP-1), 652 ± 54 mL (yohimbine) and 810 ± 37 mL (GLP-1 and yohimbine)]. Plasma noradrenaline and dihydroxyphenylglycol concentrations were higher for yohimbine vs placebo and for GLP-1 and yohimbine vs GLP-1. Yohimbine stimulates central sympathetic activity and in combination with GLP-1, augments postprandial accommodation in humans.",
keywords = "Accommodation, GLP-1, Stomach, Stress, Sympathetic, Yohimbine",
author = "Andrews, {C. N.} and Bharucha, {Adil Eddie} and Michael Camilleri and Low, {Phillip Anson} and Seide, {B. M.} and Burton, {D. D.} and Nickander, {K. K.} and Baxter, {K. L.} and Zinsmeister, {A. R.}",
year = "2007",
month = "9",
doi = "10.1111/j.1365-2982.2007.00923.x",
language = "English (US)",
volume = "19",
pages = "716--723",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans

AU - Andrews, C. N.

AU - Bharucha, Adil Eddie

AU - Camilleri, Michael

AU - Low, Phillip Anson

AU - Seide, B. M.

AU - Burton, D. D.

AU - Nickander, K. K.

AU - Baxter, K. L.

AU - Zinsmeister, A. R.

PY - 2007/9

Y1 - 2007/9

N2 - In humans, glucagon-like peptide-1 (GLP-1) delays gastric emptying by inhibiting vagal activity and also increases gastric volumes, by unclear mechanisms. Because GLP-1 inhibits intestinal motility by stimulating the sympathetic nervous system in rats, we assessed the effects of a GLP-1 agonist and yohimbine, an α2-adrenergic antagonist, on gastric volumes in humans. In this double-blind study, 32 healthy volunteers were randomized to placebo, a GLP-1 agonist, yohimbine or GLP-1 and yohimbine. Gastric volumes (fasting predrug and postdrug, and postprandial postdrug) were measured by 99mTc single photon emission computed tomography imaging. Plasma catecholamines and haemodynamic parameters were assessed. Compared with placebo, GLP-1 increased (P = 0.03) but yohimbine did not affect fasting gastric volume. However, GLP-1 plus yohimbine increased (P < 0.001) postprandial gastric accommodation vs placebo and vs GLP-1 alone [postprandial volume change = 542 ± 29 mL (mean ± SEM, placebo), 605 ± 31 mL (GLP-1), 652 ± 54 mL (yohimbine) and 810 ± 37 mL (GLP-1 and yohimbine)]. Plasma noradrenaline and dihydroxyphenylglycol concentrations were higher for yohimbine vs placebo and for GLP-1 and yohimbine vs GLP-1. Yohimbine stimulates central sympathetic activity and in combination with GLP-1, augments postprandial accommodation in humans.

AB - In humans, glucagon-like peptide-1 (GLP-1) delays gastric emptying by inhibiting vagal activity and also increases gastric volumes, by unclear mechanisms. Because GLP-1 inhibits intestinal motility by stimulating the sympathetic nervous system in rats, we assessed the effects of a GLP-1 agonist and yohimbine, an α2-adrenergic antagonist, on gastric volumes in humans. In this double-blind study, 32 healthy volunteers were randomized to placebo, a GLP-1 agonist, yohimbine or GLP-1 and yohimbine. Gastric volumes (fasting predrug and postdrug, and postprandial postdrug) were measured by 99mTc single photon emission computed tomography imaging. Plasma catecholamines and haemodynamic parameters were assessed. Compared with placebo, GLP-1 increased (P = 0.03) but yohimbine did not affect fasting gastric volume. However, GLP-1 plus yohimbine increased (P < 0.001) postprandial gastric accommodation vs placebo and vs GLP-1 alone [postprandial volume change = 542 ± 29 mL (mean ± SEM, placebo), 605 ± 31 mL (GLP-1), 652 ± 54 mL (yohimbine) and 810 ± 37 mL (GLP-1 and yohimbine)]. Plasma noradrenaline and dihydroxyphenylglycol concentrations were higher for yohimbine vs placebo and for GLP-1 and yohimbine vs GLP-1. Yohimbine stimulates central sympathetic activity and in combination with GLP-1, augments postprandial accommodation in humans.

KW - Accommodation

KW - GLP-1

KW - Stomach

KW - Stress

KW - Sympathetic

KW - Yohimbine

UR - http://www.scopus.com/inward/record.url?scp=34548179356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548179356&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2982.2007.00923.x

DO - 10.1111/j.1365-2982.2007.00923.x

M3 - Article

VL - 19

SP - 716

EP - 723

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 9

ER -